Pituitary adenoma and cerebral infarction demonstrated by Tc-99m HMPAO using a high-resolution SPECT system

Metabolic In Vivo Visualization of Pituitary Adenomas: a Systematic Review of Imaging Modalities

OBJECTIVE

Pituitary adenomas (PAs) are the most common intrasellar mass. Functional PAs constitute most of pituitary tumors and can produce symptoms related to hormonal overproduction. Timely and accurate detection is therefore of vital importance to prevent potentially irreversible sequelae. Magnetic resonance imaging is the gold standard for detecting PAs, but is limited by poor sensitivity for microadenomas and an inability to differentiate scar tissue from tumor residual or predict treatment response. Several new modalities that detect PAs have been proposed.

METHODS

A systematic review of the PubMed database was performed for imaging studies of PAs since its inception. Data concerning study characteristics, clinical symptoms, imaging modalities, and diagnostic accuracy were collected.

RESULTS

After applying exclusion criteria, 25 studies of imaging PAs using positron emission tomography (PET), magnetic resonance spectroscopy (MRS), and single photon emission computed tomography were reviewed. PET reliably detects PAs, particularly where magnetic resonance imaging is equivocal, although its efficacy is limited by high cost and low availability. Single photon emission computed tomography possesses good sensitivity for neuroendocrine tumors but its use with PAs is poorly documented. MRS consistently detects cellular proliferation and hormonal activity, but warrants further study at higher magnetic field strength.

CONCLUSIONS

PET and MRS appear to have the strongest predictive value in detecting PAs. MRS has the advantage of low cost, but the literature is lacking in specific studies of the pituitary. Due to high recurrence rates of functional PAs and low sensitivity of existing diagnostic workups, further investigation of metabolic imaging is necessary.

Imaging of pituitary tumours

In the neuroradiological study of pituitary tumours, second generation CT, dynamic CT and MRI provide information about the extent of the tumour and its anatomical relations with the surrounding tissues. Sometimes these techniques can distinguish primary anterior pituitary lesions from primary parasellar lesions with presentations in the sellar region. In general, contrast-enhanced MRI and dynamic CT are more sensitive than conventional CT for the diagnosis of pituitary microadenomas, as well as for the precise delineation of the parasellar invasion of macroadenomas. Radiological techniques usually cannot distinguish clinically non-functioning from functioning pituitary adenomas. BSIPSS is used for confirmation of the diagnosis of Cushing's disease as well as for the lateralization of pituitary microadenomas in Cushing's disease and some other anterior pituitary hyperfunctional states. Neurotransmitter-receptor ligand imaging by SPECT with 123I-IBZM and/or 111In-DTPA-octreotide characterizes the dopamine D2 and somatostatin receptor status of pituitary adenomas, respectively. In selected cases, these techniques may be used for the differential diagnosis of pituitary tumours as well as for the differential diagnosis of primary anterior pituitary lesions and primary parasellar lesions with presentations in the sellar region. If medical therapy of these tumours with receptor agonists is being considered, these techniques can help in selecting the first-line treatment. Furthermore, the effects of medical therapy on the tumour can be evaluated. The introduction of newer and more receptor-specific radioligands may expand the clinical use of these techniques in the future. The availability of PET for the clinical diagnosis of pituitary tumours is still limited, but promising results have been described.